July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Laura Bukavina: Real-World Use of ctDNA Assay in Non–Muscle-Invasive Bladder Cancer
Jun 16, 2025, 11:13

Laura Bukavina: Real-World Use of ctDNA Assay in Non–Muscle-Invasive Bladder Cancer

Laura Bukavina, Urologic Oncologist at Cleveland Clinic, posted on X:

“Practice-changing insights
ctDNA role in high risk NMIBC ( T1HG and BCG unresponsive). First pub Cleveland Clinic Urology as we continue to learn more. ctDNA is detectable in 35% of highest-risk NMIBC. ctDNA+ often flags recurrence or upstaging ~3mo before imaging.
In BCG-naïve: +ctDNA to restage with MRI to rule out cT2+
In BCG-unresponsive: +ctDNA = poor prognostic factor to favor cystectomy and lead to salvage intravesical.”

Title: Real-World Experience with a Commercial Circulating Tumor DNA Assay in Non–muscle-invasive Bladder Cancer

Authors: 

Read The Full Article at European Urology Oncology.

Laura Bukavina: Real-World Use of ctDNA Assay in Non–Muscle-Invasive Bladder Cancer

More posts featuring Laura Bukavina on OncoDaily.